In this context, the assessment of blood-based neurofilament light chain (blood-based NfL) concentration in MS is becoming a practical tool for predicting clinical outcomes and monitoring subclinical disease activity in response to treatment (9–11). The gene discussed is NEFL; the disease is myeloid sarcoma.